Molecular imaging of DNA synthesis using a new PET tracer: clinical study of diagnosis for cardiac sarcoidosis

Molecular imaging of DNA synthesis using a new PET tracer: clinical study of diagnosis for cardiac sarcoidosis - Clinical study of diagnosis for cardiac sarcoidosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030642

Enrollment

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac sarcoidosis

Interventions

The patients undergo both 4DST- and FDG-PET studies. The findings will be compared reciprocally. In the procedure, clinical findings according to the guideline of management of cardiac sarcoidosis pub

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient who is suspected cardiac sarcoidosis 2) Age, elder than or equal to 20 years. 3) Completed the written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patient who is in emargency status 2) Patient with severe comorbid disease including liver dysfunction, renal dysfunction or metabolic damage. 3) Patient with severe mental disease. 4) Patient who have possibility of pregnant, during lactation 5) Patient who have history of allergy to thyothyidine and thymidine 6) Those who are determined as not appropriate for the study by the principal investigator.

Design outcomes

Primary

Measure	Time frame
To explore how 4DST-PET can contribute to diagnosis of cardiac sarcoidosis, compared to FDG-PET.	—

Countries

Japan

Contacts

Public ContactRyogo Minamimoto

National Center for Global Health and Medicine Nuclear Medicine

rminamimoto@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026